The chromatographic determination of enantiomeric drugs and the metabolites in biological fluids is one of the most important subjects in biomedical analysis, because the individual isomers exhibit different pharmacological properties as well as pharmacokinetic and metabolic fates.
and differences due to genetic polymorphism are also encountered. 7 Nevertheless, the metabolites, diastereomeric carbinols and enatiomeric ketones, both of which are present to a large extent in a biological fluid, also have pharmacological activity 8 comparable to the parent drug. Therefore, a reliable method for the simultaneous determination of enantiomeric bufuralol along with its metabolites is essential for pharmacokinetic and pharmacodynamic studies.
Various chromatographic methods are now available for the separation and determination of enantiomers. The analytical procedure includes the use of a chiral chromatographic mode based on either chiral stationary phases or chiral eluents, and the use of a derivatization technique with a chiral reagent to produce the diastereomers, which are easily separated with a conventional separation column. [9] [10] [11] [12] [13] There are a number of chiral reagents having a reacting group to form a covalent bond with target analytes and a signal group highly responsive to a detector. 14 The reaction should proceed completely without any racemization. This method, although it is favorable for obtaining higher sensitivity, has disadvantages due to the tedious derivatization process and a clean-up procedure to remove excess reagents. Moreover, it has been shown that enantiomers can react with a chiral reagent at very different rates. 15 High-performance liquid chromatography (HPLC) employing chiral stationary phases is well recognized as a powerful tool for the direct separation of racemates. A wide variety of separation columns including the Pirkle-type, cyclodextrin-bonded, various cellulose-based, and immobilized protein columns have been developed and are commercially available.
In recent years, immunoaffinity chromatography (IAC) based on specific and reversible antigen-antibody reactions 16 has been shown to be capable of separating and determining a number of different analytes and to be a powerful analytical or pretreatment tool in biomedical analysis. In our previous study, rabbit polyclonal antibodies with high specificity for an essential chirality center have been prepared for the enantiomeric immunoaffinity extraction of optically active bufuralol and its 1′-oxidized metabolites. 17 However, it is difficult to obtain conventional polyclonal antibodies in large amounts and with identical properties, because the proportion of antibody subpopulations which are components of a polyclonal antibody varies due to individual differences between animals. Monoclonal antibodies produced by the B cell hybridoma technology have the advantage of an almost unlimited supply with identical quality and uniform specificity. Additionally, many successful results have recently been published dealing with the generation of genetically engineered antibodies or antibody-like molecules, [18] [19] [20] some of which were used for the large scale production of immunosorbents. 21 The antibodysecreting hybridomas are also useful for cloning variable region genes of an antibody which can be a starting material for preparing such an engineered antibody. From these points of view, we generated monoclonal antibodies by the hybridoma technology, which specifically recognize optically active bufuralol and its 1′-oxidized metabolites.
The resulting 31 ANALYTICAL SCIENCES JANUARY 2000, VOL. 16 2000 © The Japan Society for Analytical Chemistry antibodies were characterized in detail by competitive enzymelinked immunosorbent assay (ELISA), among which we found suitable antibodies for preparing enantiospecific immunosorbents.
Experimental

Materials
The standard compounds of (1R)-and (1S)-bufuralols, (1R)-and (1S)-1′-oxobufuralols, (1R,1′R)-, (1R,1′S)-, (1S,1′R)-and (1S,1′S)-1′-hydroxybufuralols, (1R)-and (1S)-1′-oxobufuralol O-carboxymethyl oximes were synthesized according to the methods reported previously 8, 22, 23 and their enantiomeric purities were determined by HPLC to be more than 99%. The immunogenic conjugates of (1R)-and (1S)-bufuralols with bovine serum albumin (BSA) were those previously prepared in our laboratory. 17 The mouse monoclonal antibody isotyping kit and β-galactosidase (EC 3.2. 
Medium
Medium A, RPMI 1640 medium supplemented with 10 mM HEPES buffer (pH 7.3) and kanamycin sulfate (0.1 mM); medium B, medium A supplemented with fetal bovine serum (10%, v/v), 2-mercaptoethanol (50 µM), L-glutamine (2 mM) and sodium pyruvate (1 mM); HAT medium, medium B supplemented with hypoxanthine (0.1 mM), aminopterin (0.4 µM) and thymidine (16 µM); HT medium, the same as HAT medium but does not contain aminopterin.
Buffers
Buffer A, 0.05 M NaH2PO4-Na2HPO4 (pH 7.3); buffer B, buffer A containing gelatin (0.1%), NaCl (0.9%) and NaN3 (0.1%); buffer C, buffer A containing NaCl (0.9%) and NaN3 (0.02%); buffer D, buffer C containing Tween 20 (0.05%, v/v).
Cell
P3/NS1/1-Ag4-1 myeloma cells 24 were donated by Health Science Research Resources Bank (Osaka, Japan).
Immunization, cell fusion and cloning
Female BALB/c and A/J mice (five each; 7 -8 weeks of age) purchased from Japan SLC Co. (Hamamatsu, Japan) were immunized with the BSA conjugates of (1R)-and (1S)-bufuralols at approx. 3-week intervals. The conjugate (50 µg) was injected with the emulsion (200 µl) of FCA (primary and the third booster immunization) or FIA (other booster immunizations) and sterile saline (1:1, v/v), subcutaneously in the foot pads and at multiple sites on the back. Ten days after the ninth booster injection, blood was collected from the retrobulbar plexus, and the binding ability of the serum antibodies to (1R)-and (1S)-bufuralols was determined by the ELISA procedure (see below). A month after the final booster immunization, an animal selected as the spleen donor was injected intraperitoneally with the conjugate (50 µg) dissolved in a sterile saline (200 µl), and spleen cells were prepared 3 days later. The immune spleen cells (approx. 1.0×10 8 cells) and one-fifth the number of the myeloma cells were washed with medium A, mixed together, and then fused with PEG 4000 (40%) in a sterile phosphate-buffered saline containing DMSO (10%, v/v) and poly-L-arginine·HCl (0.001%)(1 ml). After washing with medium A, the fused cells were suspended in HAT medium supplemented with HCF (10%, v/v). This cell suspension was seeded in 96-well cluster dishes (100 µl/well) and cultured overnight in a humidified atmosphere of CO2/air (5:95) at 37˚C; then HAT medium (100 µl) was added to each well. Three and 6 days after the fusion, a portion of the culture supernatant (approx.100 µl) was replaced by fresh HAT medium. After further culture for 2 -3 days, a small portion of hybridoma supernatants was taken from each well and submitted to screening by ELISA described below. The antibody-secreting hybridomas were expanded in HT medium and then cloned twice by limiting dilution in medium B supplemented with HCF (10%, v/v). Cloned hybridomas were grown in 25 cm 2 culture flasks in medium B (5 ml) untile confluence was reached. The cell suspension was centrifuged (1000×g for 15 min) at 4˚C, and monoclonal antibodies contained in the resulting supernatant were used for isotyping or ELISA for investigation of their binding characteristics.
Preparation of β-galactosidase-labeled antigen
The O-carboxymethyl oxime derivatives of (1R)-or (1S)-bufuralol (100 µg) were converted into their N-succinimidyl esters according to the reported method. 25 A solution of β-galactosidase (500 µg) in buffer A (100 µl) was added to the esters (10 mol eq. to the enzyme) in dioxane (50 µl), and the mixture was stirred at 4˚C overnight. During the coupling reaction, the solution was kept at pH 8.0 -8.5 by addition of 1 M NaOH. The resulting solution was dialyzed against buffer A at 4˚C overnight and diluted to 50 µg ml -1 with buffer A, which was stored at 4˚C until use.
Screening of antibody-secreting hybridomas
The 96-well EIA/RIA plates were coated with 100 µl/well of the second antibody diluted 1:400 with buffer A (100 µl) by overnight incubation at 4˚C. After washing three times with buffer C, the wells were blocked with 5% skimmed milk in buffer C at 37˚C for 1 h. The wells were washed three times with buffer D, to which diluted hybridoma supernatants (1:6 diluted with buffer B) (100 µl) were then added. After incubation at room temperature for 30 min with continuous shaking, the solutions were aspirated off and the wells were washed three times with buffer D. The enzyme-labeled antigen (100 ng) dissolved in buffer B (100 µl) was then added and incubated as above. After washing in the same manner, 100 µl of a buffer B containing o-nitrophenyl β-D-galactopyranoside (0.06%, v/v), MgCl2 (0.2%, v/v) and 2-mercaptoethanol (0.7%, v/v) was added, and the plates were incubated at 37˚C for 30 min. This enzyme reaction was terminated by the addition of 1 M Na2CO3 (100 µl), and the absorbance at 415 nm was measured using an MPR A4i microplate reader (Tosoh, Tokyo).
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Characterization of monoclonal antibodies
For determining the optimum dilution of the hybridoma supernatant, serially diluted supernatant with buffer B (100 µl) was added to the wells in the second antibody-coated microtiter plates, which were then incubated at room temperature for 1 h. After washing the wells as above, the enzyme-labeled antigen (100 ng) dissolved in buffer B (100 µl) was added and incubated at room temperature for 3 h. The wells were washed again and the bound enzyme activity was measured as above. Dose-response curves were constructed as follows: a solution of enzyme-labeled antigen (100 ng) in buffer B (100 µl) and a series of standard (1R)-or (1S)-bufuralol (1 -1000 pg) dissolved in buffer B (100 µl) were added to the wells which were vortex-mixed for 30 s. In each assay a blank containing buffer B was included. The hybridoma supernatant diluted with buffer B (100 µl) was added to the mixture, vortex-mixed, and incubated at room temperature for 3 h. The wells were then washed and the bound enzyme activity was measured as above (enzyme reaction=1 h). The ratios of the bound enzyme activities to those at 0 dose of (1R)-or (1S)-bufuralol were represented as B/B0.
In the cross-reaction study, the competitive antigen-antibody reaction was performed by replacing (1R)-or (1S)-bufuralol with various related compounds. The cross-reactivity of each analog was expressed as the relative amount (pg) required to reduce the initial bound enzyme activity by half, where the mass of (1R)-and (1S)-bufuralols was arbitrarily taken as 100%. 26 
Results and Discussion
Cell fusion and monoclonal antibody production
Metabolism of bufuralol mainly occurs at the C-1′ position on the aliphatic side chain to give 1′-hydroxylated bufuralols (namely carbinols), generating a new chiral center in addition to the C-1 position, which are further transformed into the 1′-ketonic derivatives. For the purpose of developing the enantioselective IAC of bufuralol and its 1′-oxidized metabolites, the antibody should have discriminating ability toward the C-1 chirality center of these compounds but should show group-specific affinity for the parent drug and its metabolites having the same configuration at the C-1 position. For this reason, the hapten-carrier conjugates, (1R)-and (1S)-1′-oxobufuralol O-carboxymethyl oxime derivatives covalently coupled with BSA (hapten/BSA molar ratio 6 for (1R)-1′-oxobufuralol O-carboxymethyl oxime and 11 for (1S)-1′-oxobufuralol O-carboxymethyl oxime), were used as the immunogens (Fig. 1) . To enhance the probability for obtaining desirable monoclonal antibodies, it seems to be very important to choose an adequate animal as a spleen donor. Although BALB/c mice are the commonest spleen donor in cell fusion, some cases have been reported where another mouse strain afforded successful results for generating a monoclonal antibody against a steroid.
27-30
Accordingly, we immunized both BALB/c and A/J mice, and the titers of the anti-bufuralol antibody in serum were compared by ELISA after the ninth booster immunization, because the opportunity for obtaining antibody-secreting hybridomas seems to be related to the strength of the humoral immune response against the target antigen which should be reflected by the serum antibody titer. The absorbance at 415 nm due to bound enzyme activities of β-galactosidase conjugated (1R)-and (1S)-bufuralols were 0.34±0.12 and 0.35±0.11 for BALB/c mice-derived antiserum and 0.50±0.08 and 0.36±0.08 for A/J mice-derived antiserum, respectively (using the 5000-fold diluted antiserum: the time of enzyme reaction was 30 min, mean±SD of five antisera from five individuals). An inhibition test was further performed by the addition of unlabeled (1R)-and (1S)-bufuralols to estimate the affinity of the elicited antibodies. Consequently, one of BALB/c mice which showed both high titer and large inhibition values was selected as the suitable spleen donor for generating monoclonal antibodies against both (1R)-and (1S)-bufuralols and was given the final immunization. The spleen cells were fused with the P3/NS1/1-Ag4-1 myeloma cells using 40% PEG 4000 supplemented with DMSO and poly-L-arginine, which were reported to increase fusion efficiency. 31 The screening by ELISA examining the binding ability to the β-galactosidaselabeled antigen demonstrated that twenty hybridomas for (1R)-bufuralol and eighteen hybridomas for (1S)-bufuralol obviously secreted an antibody. One hybridoma for (1R)-bufuralol and four hybridomas for (1S)-bufuralol were selected from these antibody-secreting cells based on the titer of their culture supernatant and the results of the inhibition experiment. Cloning of these hybridoma by limiting dilution resulted in four clones of hybridoma cell lines, derived from different microwells in their initial culture plates, one of which secretes an anti-(1R)-bufuralol antibody and the remaining three produce an anti-(1S)-bufuralol antibody.
Characterization of monoclonal antibodies
Isotypes of heavy-and light-chains of each monoclonal antibody were determined as shown in Table 1 . The binding characteristics of these antibodies were investigated by the competitive ELISA system. The optimum dilution of each antibody (hybridoma supernatant) in this ELISA was arbitrarily determined as the dilution rate affording the bound enzyme activity which corresponds to 0.6 -0.8 absorption units by onehour enzyme reaction ( Table 1 ). The absorption of nonspecific binding was below 1% of the B0 value in this ELISA system. Ab-R-12 afforded a highly sensitive dose-response curve for (1R)-bufuralol (Fig. 2) , as shown by the midpoint value (42 pg), which is the amount of antigen required to inhibit the bound enzymic activity by half (Table 1) provided less sensitive dose-response curves whose midpoints were 200, 450 and 270 pg per assay, respectively. The crossreactivities of these monoclonal antibodies were determined using various bufuralol-related compounds, and the results are listed in Table 2 . As we expected, the anti-(1R)-and (1S)-bufuralol monoclonal antibodies characteristically discriminate the corresponding antipodes as shown by their cross-reactivity of less than 1%. The Ab-R-12 showed high reactivities with 1′-oxygenated metabolites of (1R)-bufuralol (193 -160% for (1R)-1′-oxobufuralol, (1R,1R′)-and (1R,1S′)-1′-hydroxybufuralols).
On the other hand, very low cross-reactivities were observed with their corresponding (1S)-antipodes (0.07 -0.85%). A similar result was obtained for the anti-(1S)-bufuralol monoclonal antibodies. These antibodies were practically group-specific for bufuralol and its 1′-oxidized metabolites having the same configuration at the C-1 position. These binding properties would be reasonable considering the chemical structure of the immunogen used here. That is, bufuralol molecules were coupled to BSA through the C-1′ position remote from the C-1 asymmetric carbon: anti-hapten antibodies are generally specific for a partial structure on the hapten molecule which is located far from the carrier protein but do not substantially recognize a partial structure which is close to the coupling site. The antibodies prepared in this study would be available for development of both preparative and analytical IAC: the former of which constitutes a powerful pretreatment tool for various analytical methods, and the latter is an HPLC system for separating and determining enantiomers by an immobilized antibody. The high selectivity of these immunoaffinity methods enables the development of a fast and simple analytical system for complex samples. The preparative IAC based on the present monoclonal antibodies is also attractive for analytical systems based on capillary electrophoresis and liquid chromatographymass spectrometry, because it would afford greater selectivity and more informative analytical results. We are also interested in the recognition mechanism of the anti-bufuralol-monoclonal antibodies. A set of monoclonal antibodies generated here would be a good model for analyzing the structure-function relationship of the antibody paratope and a chiral epitope. ANALYTICAL SCIENCES JANUARY 2000, VOL. 16 Fig. 2 Dose-response curves of (a) (1R)-bufuralol in the ELISA using monoclonal antibody Ab-R-12 ( ) and in our previous EIA based on a rabbit antiserum ( ); 17 (b) (1S)-bufuralol in the ELISA using monoclonal antibodies Ab-S-1 ( ), Ab-S-15 ( ) and Ab-S-16 ( ) and our previous EIA based on a rabbit antiserum ( ). a. Calculated by 50% displacement method.
